Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOFT: Odanacatib in Postmenopausal Osteoporosis
NCT00529373Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2007
- Primary completion
- Nov 2012
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of odanacatib in postmenopausal osteoporosis, sponsored by Merck & Co.. Started Sep 2007; status: terminated.
02
Drugs
odanacatib
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00529373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00529373.